To receive the Femtech World newsletter, sign up here.
Entrepreneur
‘There’s a lot of medical gaslighting’: the entrepreneur shaking up the fertility industry in South Asia

Fertility treatments can be unnecessarily complicated and out of reach but they shouldn’t be, Anna Haotanto told herself when she stepped down from ABZD Capital – an investment and advisory firm she co-established – looking for a fresh start.
Inspired by her own egg freezing experience and let down by the lack of innovation in reproductive care, she set up Zora Health, a Singapore-based digital platform that aims to simplify fertility care at no extra cost for the patients. Here, she tells us more.
Anna, tell us a bit about your background and what inspired you to create Zora Health.
My last role was the managing partner of ABZD Capital and I was on the board of directors for Gourmet Food Holdings after serving as the managing director and overseeing the company’s growth in technology, digital innovation, branding, marketing and human resources.
I also founded The New Savvy – Asia’s leading financial, investments and career platform for women. Before being a founder, I was in banking for 8 years in wealth management.
I’ve been working for 22 years, and I was ready for a break and a fresh start. I stepped down last year because we reached a big milestone and I was keen to explore more tech opportunities. In that period, I looked at a lot of ideas, but asked myself, “What problem do I feel passionate about? What is overlooked and underserved?”
It’s not about proving myself, but solving something I care deeply about. I’ve always been interested in healthcare. Throughout my journey, I’ve had a lot of health issues. Last year alone, I had five surgeries. I thought I was suffering from perimenopause and started learning more about the symptoms.
It was an interesting area that I didn’t know much about. I started deep diving, because if I have that problem, I might as well try to solve it or find somebody to help. I realised there were very few solutions here. However, I couldn’t find a single source of truth or a platform of trusted resources.
So, I went into fertility as egg freezing is a topic I’m familiar with as I’ve done it myself. It’s also a very overlooked US$54bn global market, and 44 per cent of treatments are in Asia.
Technology has changed a lot of the way we do things, the way we travel, the way we stay in hotels, and the way we commute. There are a lot of developments, but not in fertility care. In Southeast Asia, I believe, there are only three or four fertility tech companies, mostly hardware or e-commerce.
I thought it was a very interesting market: high quantum, underserved. But we don’t talk about it because there are barriers to entry, such as shame and guilt.
How would you describe Zora Health in a few words?
Zora Health is a one-stop reproductive health and family planning platform that integrates patients, corporate employers, and fertility care providers, simplifying the journey and enhancing accessibility for all parties.
Our comprehensive services include online and physical consultations with a global network of partner clinics, medical concierge services and expert support. We also provide corporate fertility education workshops to cultivate fertility-friendly work environments, which ultimately help companies attract and retain top talent.
What makes Zora Health different?
Our clients often encounter common barriers, such as lack of information, stigma surrounding fertility issues and concerns about the affordability of treatments. They are also unsure of their options, what the process is like and regulations in different countries. These barriers can significantly impact their family planning journey, leading to delays or hesitations in seeking care.
At Zora Health, we strive to address these challenges by providing personalised support, educational resources and partnerships with over 80 clinics across 16 countries to empower our clients to make informed decisions about their reproductive health.
We also provide corporate fertility education workshops to cultivate fertility-friendly work environments, which ultimately help companies attract and retain top talent.
Zora means light or dawn. To us, it signifies a new beginning, a new way of doing things. We are building solutions we wished existed.
Women’s health comes with a lot of stigma. How has this impacted you as a founder?
The more stigma and problems there are, the more opportunities we see for Zora Health. The more I speak to our patients and clients, the more I see how important the work is.
Over the past few months, I realised that fertility is a problem that people address when it’s a bit too late. A younger friend of mine was told that she could only retrieve one viable egg. She’s only 37, so I think it’s a real problem. It’s just a problem that has never been talked about.
How does it impact me? The work is very meaningful and honestly, I’m very surprised to have found something that I truly love and care deeply about. We have an opportunity to change lives and make an impact. Even when I pitch to investors, I tell them I’m not here for five years — I’m here for 10, 15 years. I hope this will be my last work because there’s nothing else I want in life.
What obstacles have you encountered on this journey?
I don’t like bringing up gender issues, but the problem exists. We know that two per cent of total funding goes to women. There are a lot of female analysts and associates, but they’re not the ones writing the cheques. When I fundraised, I experienced it myself.
One of the biggest challenges for femtech is that female healthcare is poorly understood. Most of the research money historically goes to male afflictions.
There’s also a lot of medical gaslighting. When my friends see doctors, they share their discomfort but are not understood. It’s not because doctors don’t want to solve the problem, but rather that they don’t understand it. There should be more research money spent on all this.
Two, if the people writing cheques are males, they may also need help understanding, not because they don’t want to, but because they are unaware. Many years ago, when speaking to a start-up founder in his office, I saw one of my friends who needed to pump breast milk.
She complained that she had to pump in the copier room. He was completely clueless when I asked the founder why he didn’t have a private room. He was only 33. It’s not necessarily a gender problem – at 33, I didn’t have kids and I didn’t know that you needed a room for privacy and pumping breast milk.
We’ve spoken to about 400 women now, and many women don’t know about the egg freezing process. I did it five years ago, and I still didn’t know the process until I wrote an article.
Where are you with Zora Health now?
We are serving our patients and have 80 clinic partners across 16 countries. In addition, we are currently focusing on working with corporations through corporate workshops and offering corporate benefits for reproductive health and family planning. This covers the whole spectrum of fertility, menopause, PCOS, endometriosis and more.
Where do you see the company in the future?
In the long term, our vision is to unlock possibilities for women’s healthcare in Asia. To provide women with choices so they can live their lives without limitations.
To do this, we need a few things. One: resources and knowledge. It’s about creating a knowledge platform for women. And then you need providers, and a large network of clinics. And last, which people don’t talk about, is financing.
When I was young, my mum had a few surgeries because of breast cancer. I was very scared because she was not eligible for insurance by the time I could buy her insurance.
Until today, I live with that fear. What happens if she has a life-threatening disease in the future? Can I afford it? Financing is very important, and that’s often something people miss.
Maybe one day I’ll have to use my service. I’m 40 this year. Struggling with PCOS for the past six years, it will be harder for me to get pregnant. If I ever want to have kids, I believe there is a high chance I need to have IVF and if I do, I will definitely be a Zora Health patient myself.
Entrepreneur
Vespexx signs MOU with global femtech network Femtech Across Borders

Vespexx, the femtech company behind couples preconception health platform Soonr, has signed a memorandum of understanding (MOU) with Femtech Across Borders, a global femtech network supporting women’s health initiatives across 80 countries.
The agreement was signed on June 30 at Korea Femtech Summit 2026, the first global femtech summit held in Korea, hosted by Vespexx.
Femtech Across Borders is a global femtech community led by founder Rachel Bartholomew, who entered the field after her own battle with cervical cancer.
The organisation connects women’s health innovators, companies, and institutions worldwide, supporting collaboration across borders.
“For Korean femtech to reach the world, connection with the global community matters more than anything,” said Scarlett Joowon Jung, co-CEO of Vespexx.
“Through our collaboration with Femtech Across Borders, we’ll continue to strengthen our role as a bridge between Korea and the global femtech community.”
Through the MOU, the two parties will work to lower the barriers between Korean and global femtech, raising awareness of women’s health, sharing networks, and exploring future opportunities to collaborate.
Vespexx, in particular, intends to serve as a bridge connecting Korean femtech companies with the global community, widening the path for domestic companies to reach international markets.
The agreement builds on Vespexx’s recent global momentum.
On June 30, the company hosted Korea Femtech Summit 2026, bringing together femtech leaders from Korea and abroad, and used the occasion to announce the launch of Femtech Korea, an industry network that brings Korean femtech companies together and connects them with the world.
The partnership with Femtech Across Borders extends that effort outward, linking Korea’s domestic network to the global community.
Learn more about Vespexx at vespexx.com
Entrepreneur
Applications open for the third W Accelerate with Merck KGaA and M Ventures

W Group has opened applications for W Accelerate with Merck KGaA and M Ventures, inviting reproductive and maternal health startups, scaleups and spinouts to pitch for direct access to global pharma partnership and strategic investment.
Selected companies will pitch on 5th October, competing for the chance to accelerate their growth through commercial partnerships, investment, or both.
This is the third time Merck KGaA, a global leader in reproductive health, has partnered with W Group on the programme, which exists to close the innovation and investment gap in women’s health by connecting the sector’s most promising startups directly with the corporates and investors positioned to scale them.
What Merck KGaA and M Ventures are looking for
This year’s call is focused on breakthrough solutions in female infertility, fertility preservation, adenomyosis, endometriosis, polyendocrine metabolic ovarian syndrome (PMOS), ovarian insufficiency, preeclampsia and pregnancy comorbidities.
New for this round, applicants choose between three pathways depending on what they need from the programme:
- The Partnership Lane, for companies seeking commercial collaborations and strategic relationships
- The Investment Lane, for founders looking to connect with investors and secure funding to scale
- The Dual Lane, for innovators pursuing both partnership and investment opportunities
How the Accelerate event works
Selected companies get a 1:1 pitch practice session ahead of time, then a private 30-minute session with Merck KGaA and M Ventures leadership on the day itself, small-group sessions with regulatory and investment strategy experts, an “Ask Merck Anything” roundtable, and a VIP networking reception.
Key dates
- Open call launches: 8th July
- Open call closes: 2nd September
- Notification of successful companies: 11th September
- Pitch day: 5th October
Applications are open now at wplatform.typeform.com/to/KGzviBQM.
Entrepreneur
Korea’s Femtech Industry Goes Global as Vespexx Hosts Korea Femtech Summit 2026

From AI embryo analysis in India to couples fertility care launching in the US, Korea’s women’s health startups are going global, and US investors are taking notice.
Vespexx, the femtech company behind couples preconception health platform Soonr, hosted Korea Femtech Summit 2026 on June 30 in Seoul, convening founders, clinicians, and investors from Korea, Singapore, Canada, and Japan to map the global expansion of women’s health technology.
A panel moderated by Kakao Ventures’ Jade Chung, an OB/GYN-turned-investor, captured the summit’s central theme: Korean startups taking on the world. On stage were three companies already building well beyond Korea. Vespexx, led by Co-CEO Scarlett Joowon Jung, is entering the US with Soonr; Kai Health, founded by CEO Hyejun Lee, has deployed its AI embryo-analysis software across more than 120 fertility clinics in India; and Endo Health, represented by the Head of Design Karlie Hyeonjeong Koo, has built Glow, an AI coaching app whose user base is 98% women and which is backed by US investors including a16z. Together they discussed what it takes for Korean startups to compete globally, where AI creates a real edge, and whether “K-femtech” can follow the path of K-beauty onto the world stage.

The program spanned the full arc of women’s health technology. Lindsay Davis, founder of FemTech Association Asia, opened with a look at where Asia’s femtech stands today. Dr. Juhye Lee of Ewha Womans University Mokdong Hospital offered a clinician’s view of how patient needs are shifting, arguing that women’s health is expanding beyond pregnancy and treatment toward care across the entire life course. Boram Bae, Head of Digital Health PM Part at Samsung Electronics spoke to how a consumer platform at global scale can connect women’s everyday health data with life-stage care. And Rimi Lee, head of the Femtech Center at KOSDAQ-listed diagnostics company Sugentech, traced the evolution of hormone testing from results read by eye to AI-assisted analysis, and pointed toward wearable continuous hormone monitoring as the next frontier.
Vespexx Co-CEO Scarlett Joowon Jung presented the company’s “dyadic health” approach on their ‘Soonr’ app, which brings both partners into fertility and preconception care rather than tracking a woman’s data alone, an approach validated by their legacy product, Signaling’s 800,000 users across Asia, as the company prepares for US launch.
The summit also featured Rachel Bartholomew, the Canadian founder of Hyivy Health and Femtech Across Borders, who built her pelvic-health company, and Megumi Kimura of the Japan Women’s Health Innovation Association, who outlined the investment and business models driving Japan’s fast-growing femtech market.

At the summit, Vespexx also announced the launch of Femtech Korea, an industry network intended to connect Korean femtech companies with global markets and partners, and to serve as a bridge for cross-border collaboration.
“Korea has world-class healthcare technology, but femtech has been one of its best-kept secrets,” said Scarlett Joowon Jung, Co-CEO of Vespexx. “The companies on this stage are proof that’s changing. We’re not just building for Korea anymore, we’re building for the world, and we want US partners and investors to be part of that.”
Korea Femtech Summit 2026 was hosted by Vespexx and co-hosted by FemTech Association Asia. The summit was sponsored by Sugentech, with additional support from Innerness and Octolabs.
About Vespexx
Vespexx is a Korean femtech startup and subsidiary of KOSDAQ-listed biotech Sugentech. The company operates Soonr Health, a couples-focused preconception health platform, and its earlier product Signaling has accumulated over 800,000 users. Vespexx is currently expanding into the North American market.
About Femtech Association Asia
FemTech Association Asia is the region’s first and largest specialist advisory and industry network for founders, investors, corporate partners, and ecosystem contributors, with a core focus on improving women’s health through technology solutions.
Fertility1 week agoWomen with PMOS should have annual NHS checks, new guidance says
Diagnosis1 week agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Cancer7 days agoThousands of women could avoid painful cancer exam with new AI blood test
Entrepreneur2 weeks agoKorea’s Femtech Industry Goes Global as Vespexx Hosts Korea Femtech Summit 2026
News2 weeks agoBreast cancer biosensor and low-cost ultrasound startups win women’s health AI competition
News2 weeks agoClue spotlights seven women’s health journeys in new campaign
Entrepreneur6 days agoApplications open for the third W Accelerate with Merck KGaA and M Ventures
Fertility1 week agoOlder women face lower chance of fertility treatment working, even with donor eggs, study finds










